Lacerta Therapeutics
Joseph Zenkus is the current Director at Lacerta Therapeutics. Joseph has also previously held the positions of Business Development Lead at Pfizer, Director of Business Development at Sarepta Therapeutics, and Vice President of Sales & Channel Development at Mylan. Joseph Zenkus began their career as an Associate on the Healthcare Industry Team at Merrill Lynch. Joseph has a proven track record in successfully developing and implementing new business strategies and partnering solutions. Joseph Zenkus is a key player in the healthcare industry with a wealth of experience in raising capital and completing successful transactions.
Joseph Zenkus has a Master of Business Administration (MBA) from the London Business School and a Master of Science (M.Sc.) in Physical Therapy from the University of Massachusetts Lowell. Joseph also has a Bachelor of Science (BS) in Physiology from the University of Massachusetts Lowell.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Lacerta Therapeutics
Lacerta Therapeutics is a clinical stage gene therapy company using a constellation of proprietary adeno-associated virus (AAV) vector technologies to develop treatments for central nervous system and lysosomal storage diseases. With unmatched scientific expertise and depth in the development, production, and application of AAV vectors, LacertaTherapeutics is advancing its clinical programs using its proprietary capsid variants and scalable vector manufacturing platform. The experience and accomplishments of the Lacerta Therapeutics founders are unsurpassed in AAV gene therapy. In addition to world-class basic AAV vector development and gene therapy clinical trial expertise, our team brings to bear individuals with novel insight into developing novel, targeted neurological and lysosomal storage disease treatments.